Mesothelioma.com Resources for Patients and their Families

Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma

Brief Summary

The primary objective is to assess antitumor activity of the combination of bevacizumab, pemetrexed and carboplatin, in terms of time to progression.

Tracking Information
First Received DateDecember 4, 2006
Last Changed DateAugust 31, 2011
Start DateSeptember 2007
Actual Primary Completion DateNovember 2010
Primary Outcome Measures

Time to progression (TTP) from first day of treatment until first observation of disease progression or death due to any cause or the last date the patient was known to be progression free or alive. [Time Frame: At the end of study]

Secondary Outcome Measures

Response rate (RR) assessed according to modified RECIST criteria for Malignant Pleural Mesothelioma. [Time Frame: Two months after the end of enrollment]

Overall survival (OS) computed as the time between the first day of treatment and the date of death or the last date the patient was known to be alive. [Time Frame: At the end of study]

Descriptive Information
PhasePhase 2
Study TypeInterventional
Condition
  • Mesothelioma
Intervention
  • Drug: Bevacizumab, Pemetrexed, Carboplatin
Study Arms / Comparison Groups1 / 0
Detailed Description

Secondary endpoints are to evaluate:

- the objective response rate (RR) of the combination;

- the toxicity and the safety profile of the combination;

- the duration of response (RD) and time to treatment failure (TTF);

- the overall survival (OS)

- RR, TTP and OS according to baseline plasma VEGF levels (introduced with Amendment 1 dated 8/11/2007)

Recruitment Information
Recruitment StatusCompleted
Actual Enrollment77
GenderAll
Ages18 Years - N/A
Accepts Healthy VolunteersNo
Eligibility Criteria

Inclusion Criteria:

- Histologically proven malignant pleural mesothelioma, inoperable, non previously treated with chemotherapy including intracavitary administration

- PS 0-1

- Measurable and/or evaluable lesions according to RECIST criteria

- Adequate organ function

Exclusion Criteria:

- Uncontrolled hypertension

- Evidence of bleeding diathesis or coagulopathy

- Pregnancy or breast-feeding

Administrative Information
NCTIDNCT00407459
Responsible Party,
SponsorArmando Santoro, MD
Verification DateAugust 2011
Mesothelioma Doctors by State
  • Trust Funds Set Aside
  • VA Benefits Available
  • Delivered within 24 hrs

Yes   No

Mesothelioma Cancer Alliance Blog

FEATURED CONTENT:


RECENT POSTS:

National Poison Prevention Week: Household Toxins to Avoid

National Poison Prevention Week: The Dangers of Asbestos

Joe Biden Gives a Cancer Moonshot Update at SXSW Conference

Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: